
Tesamorelin
Tesamorelin Acetate
Potential Benefits
- FDA-approved for reduction of visceral adipose tissue in HIV-associated lipodystrophy
- Clinical trials demonstrated measurable reduction in trunk fat
- Research suggests potential cognitive benefits, including improved executive function in older adults
- Maintains physiologic pulsatile GH release pattern
- May support improvements in lipid profiles based on clinical data
Recommended Starting Dose
2 mg subcutaneously once daily (FDA-approved dose)
Based on published research protocols. Not a prescription.
Dosing Protocol
FDA-approved dosing is 2 mg injected subcutaneously into the abdomen once daily. Treatment duration in clinical trials ranged from 26-52 weeks. Periodic assessment of IGF-1 levels and glucose metabolism is recommended.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Clinical trials showed measurable reductions in visceral fat at 26 weeks. Some body composition changes may be noticed at 8-12 weeks.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- Injection site reactions (erythema, pruritus, pain)
- Joint pain (arthralgia)
- Peripheral edema
- Potential effects on glucose metabolism
- Hypersensitivity reactions
- May cause fluid retention
- Not recommended during pregnancy
More in Growth Hormone

CJC-1295 (no DAC) / Mod GRF 1-29
CJC-1295 without DAC
CJC-1295 without DAC (also known as Modified GRF 1-29) is a synthetic growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release growth hormone in a pulsatile fashion, mimicking the body's natural rhythm. It is often paired with a GHRP like Ipamorelin for synergistic effects.

CJC-1295 DAC
CJC-1295 with Drug Affinity Complex
CJC-1295 with DAC is a long-acting GHRH analog that includes a Drug Affinity Complex, which binds to albumin in the blood and extends its half-life to approximately 6-8 days. This results in sustained elevation of growth hormone levels rather than pulsatile release. It was developed by ConjuChem Biotechnologies.

Ipamorelin
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that acts on the ghrelin receptor to stimulate growth hormone release from the pituitary gland. It is considered one of the milder GH secretagogues, producing a targeted GH pulse without significant increases in cortisol, prolactin, or appetite. It is frequently combined with CJC-1295 (no DAC).
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.